alpha-aminopyridine has been researched along with Extranodal NK-T-Cell Lymphoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, Y; Chen, B; Dong, M; Fang, H; Guo, RY; Li, N; Li, YX; Qi, F; Qi, SN; Song, YW; Wang, SL; Wei, YC; Yang, JL; Yang, Y; Zhang, D | 1 |
| He, ZD; Hong, HY; Li, MW; Peng, ZG; Xu, QY; Yang, HY | 1 |
| Chai, Y; Chen, B; Dong, M; Fang, H; Li, YX; Liu, WP; Liu, WX; Qi, F; Qi, SN; Song, YQ; Wang, WH; Wei, YC; Xie, Y; Zhang, CG; Zhang, D; Zheng, BM; Zhu, J | 1 |
| Chen, B; Chen, J; Jiang, C; Lv, C; Wang, J; Xu, J; Xu, X | 1 |
| Dong, M; Fan, Y; Feng, J; Hong, X; Huang, H; Ke, X; Li, W; Lu, X; Ning, Z; Qi, J; Shen, Z; Shi, Y; Yu, L; Zhang, W; Zhao, X; Zhou, D; Zhu, J | 1 |
1 review(s) available for alpha-aminopyridine and Extranodal NK-T-Cell Lymphoma
| Article | Year |
|---|---|
Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Etoposide; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Extranodal NK-T-Cell; Methylprednisolone; Oxaliplatin | 2022 |
2 trial(s) available for alpha-aminopyridine and Extranodal NK-T-Cell Lymphoma
| Article | Year |
|---|---|
First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Cisplatin; Humans; Killer Cells, Natural; Lymphoma, Extranodal NK-T-Cell; Middle Aged | 2022 |
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzamides; Disease-Free Survival; Enteropathy-Associated T-Cell Lymphoma; Female; Histone Deacetylase Inhibitors; Humans; Leukopenia; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mycosis Fungoides; Neoplasm Recurrence, Local; Neutropenia; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
2 other study(ies) available for alpha-aminopyridine and Extranodal NK-T-Cell Lymphoma
| Article | Year |
|---|---|
Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
Topics: Aminopyridines; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Prospective Studies; Retrospective Studies | 2023 |
Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Histone Deacetylase Inhibitors; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nose Neoplasms; Programmed Cell Death 1 Receptor; Remission Induction; Treatment Outcome | 2021 |